Sanofi Reports Decline in Flu Vaccine Sales
Sanofi SA reported a decline in vaccine sales for the third quarter of 2025, citing reduced vaccination rates and increased pricing competition in Europe and the United States. The company’s legacy vaccine business dropped nearly eight percent to €3.36 billion (US$3.9 billion), while influenza and COVID-19 shot sales fell 17 percent to €1.53 billion (US$1.78 […]
European Commission Probes Sanofi for Possible Antitrust Violations Related to Flu Shots
French pharmaceutical company Sanofi said that European Commission (EC) officials carried out unannounced inspections at its premises in France and Germany as part of an investigation into its conduct in the seasonal influenza vaccine market.1 It is not clear whether the investigation has any impact beyond Europe, but Sanofi produces influenza vaccines for the U.S. […]
Nuvaxovid Offered as Alternative to mRNA Shots
For a virus (SARS-CoV-2) that many scientists and public health officials have maintained originated in a bat and accidently crossed over into humans, leading to the COVID-19 pandemic, it is odd that there does not appear to be much concern about producing vaccines that use genetic material from animals. You would think that this would […]